Protein conformation and diagnostic tests: The prion protein

Clinical Chemistry

Volumn 48, Issue 12, 2002, Pages 2105-2114

  Bennionn, Brian J ^a   Daggett, Valerie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PRION PROTEIN;

ANTIBODY DETECTION; CONFORMATIONAL TRANSITION; DIAGNOSTIC TEST; DYNAMICS; HUMAN; LABORATORY TEST; MUTATION; PEPTIDE ANALYSIS; PRION DISEASE; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; REVIEW;

ANIMALS; HUMANS; ORGAN SPECIFICITY; PRION DISEASES; PRIONS; PROTEIN CONFORMATION;

EID: 0036892793     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Carr CM, Chaudhry C, Kim PS. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A 1997;94:14306-13.
2. Ye S, Goldsmith EJ. Serpins and other covalent protease inhibitors. Curr Opin Struct Biol 2001;11:740-5.
3. Carrell RW, Gooptu B. Conformational changes and disease - Serpins prions and Alzheimer's. Curr Opin Struct Biol 1998;8:799-809.
4. Schiermeier Q. Testing times for BSE [News]. Nature 2001;409:658-9.
5. Giles J. Mad cow disease comes to Japan [News]. Nature 2001;413:240.
6. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:13363-83.
7. Prusiner SB. Prion diseases and the BSE crisis [Review]. Science 1997;278:245-51.
8. Sink M. Coloradoans fear the spread of a kind of mad elk disease. New York Times 2001;October 23. http://www.nytimes.com/2001/10/23/national/23ELK.html (Accessed October 2001).
9. Veneman AM. Declaration of emergency. Fed Regist 2001;66:49342-3.
10. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL, et al. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 1993;32:1991-2002.
11. Basler K, Oesch B, Scott M, Westaway D, Waelchli M, Groth DF, et al. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 1986;46:417-28.
12. Caughey B, Raymond GJ, Ernst D, Race RE. N-Terminal truncation of the scrapie-associated form of Prp by lysosomal protease(s) - Implications regarding the site of conversion of Prp to the protease-resistant state. J Virol 1991;65:6597-603.
13. Stahl N, Prusiner SB. Prions and prion proteins. FASEB J 1991;5:2799-807.
14. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991;266:18217-23.
15. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 1993;90:10962-6.
16. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, et al. Cell-free formation of protease-resistant prion protein. Nature 1994;370:471-4.
17. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT Jr, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: A model for the scrapie species barrier. Proc Natl Acad Sci U S A 1995;92:3923-7.
18. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, et al. Signal transduction through prion protein. Science 2000;289:1925-8.
19. Brown DR, Schmidt B, Kretzschmar HA. Effects of copper on survival of prion protein knockout neurons and glia. J Neurochem 1998;70:1686-93.
20. Burns CS, Aronoff-Spencer E, Dunham CM, Lario P, Avdievich NI, Antholine WE, et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 2002;41:3991-4001.
21. Alonso DOV, Daggett V. Simulations and computational analyses of prion protein conformations [Review]. Adv Protein Chem 2001;57:107-37.
22. Horiuchi M, Caughey B. Prion protein interconversions and the transmissible spongiform encephalopathies [Review]. Structure Fold Des 1999;7:R231-40.
23. (Sc) molecules with different conformations. Nat Med 1998;4:1157-65.
24. Caughey B. Interactions between prion protein isoforms: The kiss of death? [Review]. Trends Biochem Sci 2001;26:235-42.
25. Horiuchi M, Baron GS, Xiong LW, Caughey B. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J Biol Chem 2001;276:15489-97.
26. Cohen FE, Prusiner SB. Pathologic conformations of prion proteins [Review]. Annu Rev Biochem 1998;67:793-819.
27. Wadsworth JDF, Hill AF, Joiner S, Jackson GS, Clarke AR, Collinge J. Strain-specific prion-protein conformation determined by metal ions. Nat Cell Biol 1999;1:55-9.
28. Peretz D, Williamson RA, Legname G, Matsunaga Y, Vergara J, Burton DR, et al. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 2002;34:854-6.
29. Caughey B, ed. Prion Proteins. Advances in Protein Chemistry, Vol. 57. San Diego: Academic Press, 2001:405pp.
30. Alonso DOV, DeArmond SJ, Cohen FE, Daggett V. Mapping the early steps in the pH-induced conformational conversion of the prion protein. Proc Natl Acad Sci U S A 2001;98:2985-9.
31. Alonso DOV, An C, Daggett V. Simulations of biomolecules: Characterization of the early steps in the pH-induced conformational conversion of the hamster, bovine, and human forms of the prion protein. Philos Trans R Soc Lond A 2002;360:1-13.
32. Peretz D, Williamson RA, Matsunaga Y, Serban H, Pinilla C, Bastidas RB, et al. A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. J Mol Biol 1997;273:614-22.
33. Food and Drug Administration. Office of Regulatory Affairs. BSE Import Bulletin 99B-14, 2001. http://www.cfsan.fda.gov/~comm/bseimport.html (Accessed May 2000).
34. Food and Drug Administration. Center for Food Safety. Applied Nutrition: Domestic and International Cosmetic Rules, 2001. http://www.cfsan.fda.gov/~comm/cp29001.html and http://www.cfsan.fda.gov/~comm/cp29002.html (Accessed May 2002).
35. Norton SA. Raw animal tissues and dietary supplements [Letter]. N Engl J Med 2000;343:304-5.
36. Food and Drug Administration. Revised Preventative Measures for Blood Products, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3817b1.htm (Accessed May 2002).
37. Centers for Disease Control. Public Health Service Recommendations for the Use of Vaccines Manufactured with Bovine-Derived Materials, 2001. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4950a4.htm (Accessed May 2002).
38. Ferguson NM, Ghani AC, Donnelly CA, Hagenaars TJ, Anderson RM. Estimating the human health risk from possible BSE infection of the British sheep flock [Letter]. Nature 2002;415:420-4.
39. d'Aignaux JN, Cousens SN, Smith PG. Predictability of the UK variant Creutzfeldt-Jakob disease epidemic. Science 2001;294:1729-31.
40. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001;294:1726-8.
41. Kao RR, Gravenor MB, Baylis M, Bostock CJ, Chihota CM, Evans JC, et al. The potential size and duration of an epidemic of bovine spongiform encephalopathy in British sheep. Science 2002;295:332-5.
42. Moynagh J. The Evaluations of Tests for the Diagnosis of Transmissible Spongiform Encephalopathy in Bovines. European Commission, 1999. http://europa.eu.int/comm/food/fs/bse/bse12_en.html (Accessed May 2002).
43. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183-9.
44. Bieschke J, Giese A, Schulz-Schaeffer W, Zerr I, Poser S, Eigen M, et al. Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Nat Acad Sci U S A 2000;97:5468-73.
45. Kneipp J, Beekes M, Lasch P, Naumann D. Molecular changes of preclinical scrapie can be detected by infrared spectroscopy. J Neurosci 2002;22:2989-97.
46. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-7.
47. Jennifer Rufer v. Abbott Laboratories and the University of Washington Medical Center. Benyon, M. Case 99-2-270908-Seattle (King County Superior Court, 2001).
48. Alperovitch A. Epidemiology of Creutzfeldt-Jakob disease - Past and present uncertainties. Eur J Neurol 1996;3:500-6.
49. Deslys JP, Comoy E, Hawkins S, Simon S, Schimmel H, Wells G, et al. Public health - Screening slaughtered cattle for BSE [Communication]. Nature 2001;409:476-8.
50. European Commission. Opinion of the SSC on Design of a Field Trial for the Evaluation of New Rapid BSE Post Mortem Tests. Scientific Steering Committee, 2002. http://europa.eu.int/comm/food/fs/sc/ssc/out246_en.pdf (Accessed May 2002).
51. Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, Famulok M, et al. RNA aptamers specifically interact with the prion protein PrP. J Virol 1997;71:8790-7.
52. Sc-specific nucleic acids, method for their production, and diagnostic and therapeutic use. PCT Int Appl Wo (Lasmezas, Corinne Ida, Fr), 2000:48pp.
53. Hope J, Roth N, Hatigi L, Watson S, Richmond-Chew T, Wiltshire V, et al. High Efficiency Removal of Prion Proteins from Red Cell Concentrates by the INACTINE™ Process. Watertown, MA: VI Technologies Inc, 2001.
54. James WS. Nucleic acid aptamer ligands specific for an isoform of the prion protein. PCT Int Appl Wo (Isis Innovation Limited, UK), 2001:46 pp.
55. Schmerr MJ, Jenny AL, Bulgin MS, Miller JM, Hamir AN, Cutlip RC, et al. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatogr A 1999;853:207-14.
56. Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 2001;137:5-13.
57. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001;276:31479-82.
58. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding [Letter]. Nature 2001;411:810-3.
59. Miele G, Manson J, Clinton M. A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat Med 2001;7:361-4.
60. Caughey B, Race RE. Potent inhibition of scrapie-associated Prp accumulation by Congo red. J Neurochem 1992;59:768-71.
61. Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated Prp accumulation in cultured-cells. J Virol 1993;67:643-50.
62. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A 1998;95:12117-22.
63. Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000;287:1503-6.
64. Supattapone S, Nguyen HOB, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999;96:14529-34.
65. Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci U S A 2000;97:6073-8.
66. Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-7.
67. Perovic S, Pialoglou P, Schroder HC, Pergande G, Muller WE. Flupirtine increases the levels of glutathione and Bc1-2 in hNT (human Ntera/D1) neurons: Mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996;317:157-64.
68. Otto M, Boekhoff I, Ratzka P, Wiltfang J, Riedemann C, Kropp S, et al. First therapeutic experience with flupirtine in patients with Creutzfeldt-Jakob disease. J Neurol 1998;245:846.
69. Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001;98:9836-41.
70. Stewart LR, White AR, Jobling MF, Needham BE, Maher F, Thyer J, et al. Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 2001;65: 565-72.
71. Will RG, Knight RSG. Potential Treatments for Creutzfeldt-Jakob Disease, 2002. http://www.cjd.ed.ac.uk/TREAT.htm (Accessed May 2002).
72. First CJD Drug Trial Patient Dies, 2001. http://news.bbc.co.uk/1/hi/health/1687339.stm (Accessed July 2002).
73. Aguzzi A, Glatzel M, Montrasio F, Prinz M, Heppner FL. Interventional strategies against prion diseases. Nat Rev Neurosci 2001;2:745-9.
74. Oldstone MB, Race R, Thomas D, Lewicki H, Homann D, Smelt S, et al. Lymphotoxin-α- and lymphotoxin-β-deficient mice differ in susceptibility to scrapie: Evidence against dendritic cell involvement in neuroinvasion. J Virol 2002;76:4357-63.
75. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity [Letter]. Nature 2001;412:739-43.
76. Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, Rozenshteyn R, et al. Mapping the prion protein using recombinant antibodies. J Virol 1998;72:9413-8.
77. Leclerc E, Peretz D, Ball H, Sakurai H, Legname G, Serban A, et al. Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form. EMBO J 2001;20:1547-54.
78. Sc)-specific epitope defined by a monoclonal antibody [Letter]. Nature 1997;390:74-7.
79. James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, et al. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci U S A 1997;94:10086-91.
80. C glycoform heterogeneity as a function of brain region: Implications for selective targeting of neurons by prion strains. J Neuropathol Exp Neurol 1999;58:1000-9.
81. Garcia FL, Zahn R, Riek R, Wuthrich K. NMR structure of the bovine prion protein. Proc Natl Acad Sci U S A 2000;97:8334-9.
82. Zahn R, Liu AZ, Luhrs T, Riek R, von Schroetter C, Garcia FL, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 2000;97:145-50.